Biodefense Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 17.79 Billion |
| Market Size (2029) | USD 26.30 Billion |
| CAGR (2024 - 2029) | 8.13 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Biodefense Market Analysis
The Global Biodefense Market size is estimated at USD 17.79 billion in 2024, and is expected to reach USD 26.30 billion by 2029, growing at a CAGR of 8.13% during the forecast period (2024-2029).
The biodefense market is driven by factors such as the increasing investment by governments in developed countries and rising government initiatives. Governments are introducing various initiatives to expand their research and development capabilities to meet future biological threats. For instance, in June 2023, the Biological Security Strategy of the United Kingdom aimed to protect the country from domestic and global biological risks and threats.
The government allocated EUR 1.5 billion (USD 1.6 billion) annually to support the Biological Security Strategy (BSS) in the United Kingdom in 2022. It formalizes the government’s biosecurity leadership, governance, and accountability structures to invest in the United Kingdom’s real-time biosurveillance and detection capabilities and lead internationally in establishing standards of best practice for responsible innovation. Such a high budget allocation is anticipated to fuel the growth of the market during the forecast period.
The rapid technological advancements, such as product launches and mergers by the key market players in the country, are also expected to propel market growth over the forecast period. For instance, in January 2022, Integrated Viral Protection (IVP), a Texas-based technology business, released a new portable air filtration equipment that can eliminate airborne viruses in a single pass, including sub-micron versions producing COVID-19, anthrax spores, allergens, and other dangerous respiratory triggers. The patented biodefense indoor air protection system eradicates SARS-CoV-2 (99.99%), anthrax spores (99.98%), and other airborne infections in a single pass.
The emerging trends in the biodefense market include the development of new vaccines and therapeutics, the use of nanotechnology for detection and decontamination, and the use of synthetic biology for the development of novel countermeasures. Nanoparticles can be engineered to target specific pathogens quickly, potentially accelerating the development of vaccines against emerging threats. For instance, the Journal of Neuroscience, in May 2023, stated that the ability to detect and respond to biological threats has been greatly improved through the development of nanoscale biosensors. These sensors can identify specific pathogens or toxins with remarkable speed and accuracy, offering vital tools for biodefense.
Therefore, factors such as the rising investment by governments in developed countries, such as the United States, and rapid technological advancements are expected to boost the market growth over the forecast period. However, low penetration in developing and underdeveloped countries may restrain market growth.
Biodefense Market Trends
The Anthrax Segment is Expected to Witness Healthy Growth in the Market Over the Forecast Period
Anthrax is a serious infectious disease caused by gram-positive, rod-shaped bacteria known as Bacillus anthracis. It occurs naturally in soil and commonly affects domestic and wild animals around the world. People can get sick with anthrax if they encounter infected animals or contaminated animal products.
The anthrax segment is fueled by factors such as the increased outbreak of anthrax among the human population, favorable government initiatives, and R&D initiatives by companies. For instance, as per the European Centre for Disease Prevention and Control (ECDC) Communicable Disease Threat Report, in July 2022, the media reported 15 human cases of cutaneous anthrax linked to an anthrax outbreak in cattle in the Sisak-Moslavina County following heavy rain in the area. Furthermore, in July 2022, the Croatian Ministry of Agriculture issued an order containing measures to prevent the emergence and spread of anthrax in the affected area. The measures include closure of affected areas, vaccination of animals, and additional prevention measures relating to humans.
The presence of competitors, mergers, acquisitions, product launches, and R&D initiatives are expected to boost the market growth. For instance, in January 2024, Emergent BioSolutions Inc. (EBS) signed a procurement contract for a maximum value of up to USD 235.8 million with the US Department of Defense (DoD) to supply its anthrax vaccine BioThrax. The vaccine is intended for use by all branches of the US military as pre-exposure prophylaxis (PrEP) for anthrax disease. This procurement contract is a five-year agreement plan with an extension option up to 2033. Additionally, in January 2023, Emergent BioSolutions Inc. received the US-FDA approval for CYFENDUS (anthrax vaccine adsorbed, adjuvanted), previously known as AV7909, for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis.
Therefore, the anthrax segment is expected to witness significant growth over the forecast period due to advancements in anthrax detection and manufacturers focusing on contract agreements and receiving approval from the authorities.
North America is Expected to Hold a Significant Market Share Over the Forecast Period
The primary growth drivers of the biodefence market in North America are the increasing investment and initiatives by the government and rapid technological advancements in the country. For instance, as per the 2022 report from the National Association of County and City Health Officials, to address biological threats, the National Health Security Strategy (NHSS) and National Biodefense Strategy (NBS) focused on advancing the US health security enterprise through prevention, preparedness, response, recovery, and mitigation efforts to combat infectious disease and biological threats.
Additionally, in August 2023, the Department of Defense released the Biodefense Posture Review, outlining reforms aimed at the department's posture to fight and win in the face of future threats. The Biodefense Posture Review was a whole enterprise that came together during COVID-19 response efforts and, building on that collaboration, developed guidance to achieve National Defense Strategy priorities and address biological threats, especially those with strategic consequences for the US military. The high number of initiatives taken by government agencies for biodefense is expected to boost the market expansion during the forecast period.
Furthermore, as per the immediate release in August 2022 from the US Department of Health & Human Services, it facilitated an agreement between Bavarian Nordic and Grand River Aseptic Manufacturing (GRAM), a Michigan-based pharmaceutical contract manufacturer, to establish the first fill and finish line for the JYNNEOS vaccine in the United States. The vaccine is indicated for the prevention of smallpox and monkeypox. Furthermore, as per the news published in May 2022, Public Services and Procurement Canada issued a tender to purchase 500,000 doses of the Imvamune smallpox vaccine on behalf of the Public Health Agency of Canada from 2023 to 2028. The high number of people facing smallpox further raises the need for a smallpox vaccine in Canada, and it is anticipated to increase market expansion during the forecast period.
Therefore, factors such as rapid technological advancements, increasing investments and initiatives by governments, and the rising cases of smallpox in North America are expected to boost market growth over the forecast period.
Biodefense Industry Overview
The biodefence market is consolidated in nature due to the limited number of companies operating globally and regionally. The biodefense market consists of players such as Emergent BioSolutions Inc., Siga Technologies Inc., Bavarian Nordic, Nighthawk Biosciences Inc. (Elusys Therapeutics Inc.), and Ichor Medical Systems. Many companies are getting funds from governments and developing vaccines or products that are beneficial in terms of national biosecurity.
Biodefense Market Leaders
-
Siga Technologies Inc.
-
Emergent BioSolutions Inc.
-
Nighthawk Biosciences, Inc. (Elusys Therapeutics Inc.)
-
Dynavax Technologies
-
Ichor Medical Systems
*Disclaimer: Major Players sorted in no particular order
Biodefense Market News
- March 2024: Emergent BioSolutions Inc. (EBS) developed BioThrax, a vaccine approved by the US Food and Drug Administration (FDA) for pre-exposure prophylaxis and post-exposure prophylaxis of anthrax disease. The company is actively participating to uphold its position as the prominent manufacturer of anthrax vaccines to various organizations.
- September 2023: T2 Biosystems Inc. received the US FDA approval for its T2Biothreat Panel, which aids in detecting six high-priority biothreat pathogens in the United States. The T2Biothreat Panel is a direct-from-blood molecular diagnostic test that runs on the T2Dx instrument, which can detect and differentiate between six biothreat pathogens in a single sample, including the organisms that cause anthrax (Bacillus anthracis), tularemia (Francisella tularensis), glanders (Burkholderia mallei), melioidosis (Burkholderia pseudomallei), plague (Yersinia pestis), and epidemic typhus (Rickettsia prowazekii).
Global Biodefense Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Investment and Initiatives by the Governments in Developed Countries
4.2.2 Rapid Technological Advancements
4.3 Market Restraints
4.3.1 Low Penetration in Developing and Underdeveloped Countries
4.4 Porter Five Forces
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Product
5.1.1 Anthrax
5.1.2 Botulism
5.1.3 Smallpox
5.1.4 Nuclear
5.1.5 Other Products
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Emergent BioSolutions Inc.
6.1.2 Siga Technologies Inc.
6.1.3 Bavarian Nordic
6.1.4 National Resilience Inc.
6.1.5 Ichor Medical Systems
6.1.6 Nighthawk Biosciences Inc. (Elusys Therapeutics Inc.)
6.1.7 Dynavax Technologies
6.1.8 XOMA Corporation
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Biodefense Industry Segmentation
As per the scope of the report, biodefense constitutes the use of medical measures to protect individuals against bioterrorism, including interventions such as drugs and vaccinations. Furthermore, there is an improvement in terms of research and public health preparations to fight against biological attacks. There is an increasing awareness regarding synthetic biology, mainly for using biological organisms to reduce the burden of diseases, especially for improving agricultural yields.
The biodefense market is segmented by product and geography. By product, the market is segmented into anthrax, botulism, smallpox, nuclear, and other products. The other products segment includes viral hemorrhagic fever, brucellosis, cholera, influenza, plague, food poisoning, tularemia, Zika, and Ebola. The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers market sizes and forecasts in terms of value (in USD) for the above segments.
| By Product | |
| Anthrax | |
| Botulism | |
| Smallpox | |
| Nuclear | |
| Other Products |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Biodefense Market Research FAQs
How big is the Global Biodefense Market?
The Global Biodefense Market size is expected to reach USD 17.79 billion in 2024 and grow at a CAGR of 8.13% to reach USD 26.30 billion by 2029.
What is the current Global Biodefense Market size?
In 2024, the Global Biodefense Market size is expected to reach USD 17.79 billion.
Who are the key players in Global Biodefense Market?
Siga Technologies Inc., Emergent BioSolutions Inc., Nighthawk Biosciences, Inc. (Elusys Therapeutics Inc.), Dynavax Technologies and Ichor Medical Systems are the major companies operating in the Global Biodefense Market.
Which is the fastest growing region in Global Biodefense Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Biodefense Market?
In 2024, the North America accounts for the largest market share in Global Biodefense Market.
What years does this Global Biodefense Market cover, and what was the market size in 2023?
In 2023, the Global Biodefense Market size was estimated at USD 16.34 billion. The report covers the Global Biodefense Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Biodefense Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global Biodefense Industry Report
The global market for Biodefense is comprehensively analyzed in this industry report, which covers various segments such as Anthrax, Botulism, Smallpox, Nuclear, and other products. The market size and market share are detailed across different geographies, including North America, Europe, Asia-Pacific, Middle East, Africa, and South America. This market analysis provides valuable insights into the market trends and market growth, offering an extensive market forecast outlook.
Industry reports indicate that the biodefense market is poised for significant growth, driven by increasing investments and advancements in technology. The industry analysis highlights the critical role of market leaders in shaping the market dynamics. Market research and market data are crucial for understanding the current market value and predicting future market segmentation.
The report example includes detailed industry information and industry statistics, which are essential for stakeholders to make informed decisions. The industry outlook and market overview sections provide a comprehensive review of the market predictions and market trends. The report pdf, available for download, offers an in-depth market review and market forecast, supported by extensive industry research and market data.
Research companies play a pivotal role in providing accurate industry sales and industry size information, which is crucial for understanding the market growth rate. The industry trends and market outlook sections of the report highlight the key factors driving the market growth and the potential challenges that may arise.
In conclusion, this industry report on the biodefense market offers a thorough analysis of the market value, market segmentation, and market predictions. The report is an invaluable resource for stakeholders seeking to understand the market dynamics and make strategic decisions based on comprehensive industry research and market data.
